Insulet Corp. · Healthcare
Paid for today, but breaks on a small cut — or only looks over-priced at a 9% discount rate.
At a 13.0% margin the price requires 12.1% 3y revenue CAGR against 15.3% consensus, a cushion of -3.4pt versus a 0pt correction cut. Cushion is negative at the panel margin but turns positive 1pt lower in the discount rate, so it hangs on the rate and the margin. Own-story overhang; no AI channel.
Would recover if: manufacturing defects and class actions dent the 15.3% CAGR. We re-check this against analyst estimates every evening.
10 years, at a 13% margin analysts expect
+10.1%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
19 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 111% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 12, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the very bottom of the published model range, 27% below the median target, meaning the market completely rejects the bull case and prices a steep deceleration from the 30.7% growth just delivered.
Whether the manufacturing defects and lawsuits permanently impair Insulet's market share and growth trajectory, or whether unit volume trends remain intact despite the overhang — a question that available unit volume data can help settle.
What the price refuses to pay for, and the full reconstruction, on the PODD quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names